Filter by Event: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018
Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design.
Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design. Lead author: MD Huband, presented at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2492
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres.
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2432
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program.
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2434
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres.
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2431
Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China.
Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1662
Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum.
Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum. Lead author: HS Sader presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1817
Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents.
Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1805
In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results.
In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results. Lead author: MD Huband, presented in European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1822
Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017).
Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1807
Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa.
Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1661
Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections.
Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1671
Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens.
Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1672
Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017).
Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017). Lead author: LR Duncan, presented at the 28th European Congress of Clinical Microbiology and Infections Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1808
Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017).
Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1806
Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016.
Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1140
Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016).
Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016). Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0929
The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016).
The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: AC Gales, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1104
Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13).
Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, Madrid, Spain
# P0606
In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program.
In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0599
Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program.
Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1073
Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016.
Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1043
Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016).
Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016). Lead author HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0102
Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101.
Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101. Lead author: MD Huband, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
#P0157
Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016.
Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Lead author: MA Pfaller, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0323
Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms.
Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms. Lead author: M Castanheira presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0093
